铝镁匹林片(Ⅱ)治疗稳定型缺血性心脏病的作用及不良反应

Effects and adverse reactions of Aluminum-Magnesium and Aspirin Tablets(Ⅱ) on stable ischemic heart disease

目的评价铝镁匹林片(Ⅱ)对稳定型缺血性心脏病患者血小板聚集功能及胃肠道反应。方法选取2015年1月～2016年5月在成都医学院第一附属医院心内科就诊需要服用阿司匹林及氯吡格雷双联抗血小板聚集的稳定型缺血性心脏病患者587例为研究对象,依据随机数字表法分成A、B、C三组。A组195例,采用单纯的氯吡格雷治疗;B组196例,采用阿司匹林肠溶片联合氯吡格雷治疗;C组196例,采用铝镁匹林片(Ⅱ)联合氯吡格雷治疗。比较用药前及用药30 d后的血小板聚集率、疗效和不良反应发生率。结果经30 d治疗后,三组患者的血小板聚集率均低于用药前(P <0.05)。三组患者用药后的血小板聚集率不全相同(P <0.05)。用药后A组的血小板聚集率高于B、C组(P <0.01);B组用药后的血小板聚集率与C组比较,差异无统计学意义(P> 0.05)。三组心绞痛疗效差异无统计学意义(P> 0.05)。不良反应事件中,三组心血管不良事件发生率比较,差异无统计学意义(P> 0.05);C组胃肠不良反应发生率低于A、B组(P <0.05)。结论铝镁匹林片(Ⅱ)对稳定型缺血性心脏病患者具有较好的临床疗效,且胃肠道的不良反应少。

Objective To evaluate the effect of Aluminum-Magnesium and Aspirin Tablets （ Ⅱ ） on the platelet aggregation function and gastrointestinal reaction for stable ischemic heart disease. Methods A total of 587 patients with stable ischemic heart disease requiring Aspirin and Clopidogrel dual antiplatelet aggregation treated in the Department of Cardiology, the First Affiliated Hospital of Chengdu Medical College from January 2015 to May 2016 were selected. They were divided into A, B, C group. 195 cases of group A were treated with Clopidogrel, 196 cases of group B were treated with Aspirin and Clopidogrel, and 196 cases of group C were treated with Aluminum-Magnesium and Aspirin Tablets （ Ⅱ ）. The platelet aggregation rate, efficacy before and after 30 days＇ treatment, incidence of adverse reactions were compared among the three groups. Results The platelet aggregation rate after 30 days＇ treatment of the three groups were lower than that before treatment （P 〈 0.05）. After treatment, the platelet aggregation rate among the three groups were statistically different （P 〈 0.05）. After treatment, the platelet aggregation rate in group A was higher than that in group B and C （P 〈 0.01）; while the platelet aggregation rate had no difference between group B or C （P 〉 0.05）. The treatment effect of all groups of anginas had no statistically significant difference （P 〉 0.05）. There was no significant difference in the incidence of cardiovascular adverse events among the three groups （P〉 0.05）. The incidence of gas- trointestinal adverse reactions was lower in group C than that in groups A and B （P 〈 0.05）. Conclusion Aluminum- Magnesium and Aspirin Tablets （Ⅱ） has good clinical efficacy in patients with stable ischemic heart disease, and have fewer gastrointestinal adverse reactions.